Redhill Biopharma Ltd - ESG Rating & Company Profile powered by AI
This ESG rating for Redhill Biopharma Ltd represents its reporting of the UN Sustainable Development Goals. Jump to the bottom of this webpage for potential risks for Redhill Biopharma Ltd based on industry, location and size. This webpage displays a free Sustainability assessment for Redhill Biopharma Ltd.
Redhill Biopharma Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.1; made up of an environmental score of 4.0, social score of 6.4 and governance score of 4.8.
5.1
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 687 | Valbiotis SA | 5.2 | High |
| 687 | Zeria Pharmaceutical Co Ltd | 5.2 | High |
| 724 | Redhill Biopharma Ltd | 5.1 | High |
| 724 | Catalyst Pharmaceuticals Inc | 5.1 | High |
| 724 | Adverum Biotechnologies Inc | 5.1 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Redhill Biopharma Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Redhill Biopharma Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Redhill Biopharma Ltd report the average age of the workforce?
Sign up for free to unlockDoes Redhill Biopharma Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Redhill Biopharma Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Redhill Biopharma Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Redhill Biopharma Ltd offer flexible work?
Sign up for free to unlockDoes Redhill Biopharma Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Redhill Biopharma Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Redhill Biopharma Ltd conduct supply chain audits?
Sign up for free to unlockDoes Redhill Biopharma Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Redhill Biopharma Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Redhill Biopharma Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Redhill Biopharma Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Redhill Biopharma Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Redhill Biopharma Ltd disclose water use targets?
Sign up for free to unlockDoes Redhill Biopharma Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Redhill Biopharma Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Redhill Biopharma Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Redhill Biopharma Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Redhill Biopharma Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Redhill Biopharma Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Redhill Biopharma Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Redhill Biopharma Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Redhill Biopharma Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Redhill Biopharma Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Redhill Biopharma Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Redhill Biopharma Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Redhill Biopharma Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Redhill Biopharma Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Redhill Biopharma Ltd disclose its waste policy?
Sign up for free to unlockDoes Redhill Biopharma Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Redhill Biopharma Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Redhill Biopharma Ltd disclose energy use targets?
Sign up for free to unlockDoes Redhill Biopharma Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Redhill Biopharma Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Redhill Biopharma Ltd
These potential risks are based on the size, segment and geographies of the company.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.